Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 7, 2015

French Hospital to Drop Remicade in Favor of a Biosimilar

A large health system will use the biosimilar version of infliximab from Hospira after the company offered a discount of 45%.

Reuters reports that after receiving a 45% discount from Remicade (infliximab), the central purchasing agency for the Assistance Publique-Hôpitaux de Paris (AP-HP) will use the biosimilar version of infliximab instead of branded Remicade.

Remicade accounts for 25% of Johnson & Johnson’s pharmaceutical revenues, according toForbes. Although the patent for Remicade expired in Europe, giving way to biosimilars for that product, the US patent for Remicade does not expire until 2018.

The biosimilar for infliximab was sold to Norway recently for a 69% discount, an even better deal than what France received, though Reuters reports that it was from another supplier. Despite the fact that many analysts initially estimated that biosimilar discounts would be around 15–20%, in reality, the discounts have been significantly larger, a fact that may force branded drug manufacturers to re-evaluate their pricing strategies. 


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.